Molecular epidemiology of multidrug-resistant Acinetobacter baumannii in a single institution over a 10-year period by Runnegar, N. et al.
JOURNAL OF CLINICAL MICROBIOLOGY, Nov. 2010, p. 4051–4056 Vol. 48, No. 11
0095-1137/10/$12.00 doi:10.1128/JCM.01208-10
Copyright © 2010, American Society for Microbiology. All Rights Reserved.
Molecular Epidemiology of Multidrug-Resistant Acinetobacter baumannii
in a Single Institution over a 10-Year Period
Naomi Runnegar,1,2* Hanna Sidjabat,3 H. M. Sharon Goh,4 Graeme R. Nimmo,1,2
Mark A. Schembri,4 and David L. Paterson1,3
Pathology Queensland Central Laboratory, Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia1; University of
Queensland, Brisbane, Queensland, Australia2; University of Queensland Centre for Clinical Research, Royal Brisbane and
Women’s Hospital, Brisbane, Queensland, Australia3; and School of Chemistry and Molecular Biosciences,
University of Queensland, Brisbane, Queensland, Australia4
Received 15 June 2020/Returned for modification 26 June 2010/Accepted 16 August 2010
Multidrug-resistant Acinetobacter baumannii is a worldwide nosocomial menace. We sought to better under-
stand its behavior through studying the molecular epidemiology of this organism at the Royal Brisbane and
Women’s Hospital, Brisbane, Queensland, Australia, over a 10-year period. Multilocus sequence typing
(MLST), semiautomated repetitive sequence-based PCR (rep-PCR), and pulsed-field gel electrophoresis
(PFGE) were performed on a selection of 31 A. baumannii isolates collected over the 10-year period to
determine their relationships to one another. MLST also allowed us to put this information in a global context.
The presence or absence of blaOXA-23 was also established. The presence of blaOXA-23 closely correlated with
carbapenem resistance in our collection. Sequence type 92 (ST92) was the dominant sequence type and was
present in the hospital for 9 years. There was also evidence of the spread of ST69, ST73, and ST125 (novel)
within the hospital, but this was not sustained over long periods. There were only single examples of the novel
sequence types ST126 and ST127. The different typing methods clustered the isolates similarly; however, PFGE
and rep-PCR were more discriminatory than MLST. Worldwide, ST92 and the associated clonal complex 92
represent the most sampled and widespread sequence type(s) and are also known as European clone 2 and
worldwide clonal lineage 2. Antibiotic susceptibility within ST92 is variable, suggesting a role for mechanisms
other than antibiotic resistance in its success.
Acinetobacter baumannii is a nonfermentative Gram-nega-
tive bacillus which is notable for its ability to acquire antibiotic
resistance determinants and cause hospital outbreaks of infec-
tion (23). A. baumannii is an important pathogen of critically ill
patients and can cause a range of infections, including venti-
lator-associated pneumonia, bloodstream infection, wound in-
fection, and nosocomial meningitis (13, 15, 23). In many insti-
tutions, substantial difficulties arise because A. baumannii
strains have become resistant to all beta-lactam antibiotics
(including carbapenems), all fluoroquinolones, trimethoprim-
sulfamethoxazole, and most, if not all, aminoglycosides (24).
Thus, empirical treatment choices are extremely limited.
In order to better control multidrug-resistant A. baumannii
(MRAB), an understanding of the molecular epidemiology of
the infection is necessary. From a global perspective, it is
known that A. baumannii is typically clonal in nature (11).
Three clonal complexes (CCs) have predominated in Europe
for more than a decade (6, 28); these clonal complexes have
more recently also been documented in North America, Asia,
Africa, and Australia (11). The precise origin of these clonal
lineages will likely never be known. From this broader geo-
graphic perspective, it is remarkable how successful clones
have spread, likely through the international transfer of pa-
tients (11, 22).
The molecular epidemiology of A. baumannii has typically
been studied in the context of outbreaks of infection. However,
an understanding of the epidemiology of the infection over
longer time periods may allow new insights into the behavior of
this emerging pathogen. In the study described in this paper,
we have undertaken a longitudinal evaluation of the molecular
epidemiology of multidrug-resistant A. baumannii in a single
institution over a 10-year period.
MATERIALS AND METHODS
Setting. The Royal Brisbane and Women’s Hospital (RBWH) is a 900-bed
teaching hospital of the University of Queensland. The hospital is a major
referral center for trauma, burns, and hematologic transplantation. Within the
hospital is a 19-bed long-stay intensive care unit (ICU), which has a bed occu-
pancy of from 550 to 670 patient days per month.
Isolates and time period. Isolates were selected from a collection of all A.
calcoaceticus-A. baumannii complex strains with non-wild-type susceptibility pro-
files that had been cultured at RBWH between September 1998 and November
2008. A non-wild-type susceptibility profile was defined as resistance, by use of
the Vitek GNI card, to trimethoprim-sulfamethoxazole, gentamicin, tobramycin,
amikacin, ceftazidime, cefepime, ticarcillin-clavulanate (Timentin), piperacillin-
tazobactam (Tazocin), ciprofloxacin, or meropenem for any isolate.
There were 483 isolates from unique patients available. The vast majority of
isolates in the collection had been cultured from patients in the ICU or burns
ward. The dominant phenotype was susceptibility only to amikacin or to amika-
cin and tobramycin (the isolates were not routinely tested for colistin and tige-
cycline susceptibility). More than half of the isolates collected over the 10-year
period were from 2001-2002 (n  204) and 2006 (n  84); these periods corre-
sponded to A. baumannii outbreaks in the hospital.
From this collection, a total of 33 isolates were selected for study. Seventeen
isolates were from outbreak periods. Of these, seven isolates had a pulsed-field
gel electrophoresis (PFGE) profile demonstrating a close or possible relationship
to the outbreak strain, six were different from the outbreak strain by PFGE, and
four isolates were not typed by PFGE. Sixteen isolates were from sporadic cases.
* Corresponding author. Present address: Infection Management
Services, Princess Alexandra Hospital, 199 Ipswich Road, Woolloong-
abba, Queensland 4102, Australia. Phone: 617 3176 7177. Fax: 617
3176 5540. E-mail: Naomi_Runnegar@health.qld.gov.au.











These isolates were selected because there was a point of difference in the
antibiotic susceptibility profile or epidemiology (known international transfer or
lack of association with the burns unit or ICU) or to allow representation of
isolates from all years.
Species identification, antimicrobial susceptibility, and detection of carbap-
enemases. Phenotypic identification and antibiotic susceptibility testing were
performed by use of the Vitek or Vitek 2 system (bioMe´rieux, France), and the
results were interpreted according to CLSI criteria (4). Genotypic identification
as A. baumannii was confirmed by detection of blaOXA-51-like by a real-time PCR
assay adapted from the gel-based method described previously (26). PCRs were
performed using 20-l reaction mixtures with 10 pmol each of forward and
reverse primers, 7 l of water, 10 l of Platinum SYBR green quantitative PCR
Supermix-UDG (Invitrogen, Carlsbad, CA), and 1 l of extracted DNA. Am-
plification and detection were performed on a Rotor-Gene 6000 real-time system
(Corbett Research, Sydney, Australia) under the following conditions: 94°C for
3 min and 35 cycles of 94°C for 45 s, 60°C for 45 s, and 72°C for 1 min, followed
by a final extension of 72°C for 1 min.
Detection of blaOXA-23 (commonly associated with carbapenem resistance)
was performed as described previously (2).
MLST. Multilocus sequence typing (MLST) was performed as described pre-
viously (3), with the following exceptions: amplification of gyrB and gpi was
performed with an annealing temperature of 50°C for some isolates, as product
generation was inefficient at 55°C. The amplification product was purified with
ExoSAP-IT reagent (Axygen, Union City, CA). Sequencing was performed with
BigDye Terminator cycle sequencing kit premix version 3 and an ABI 3730 DNA
analyzer (Applied Biosystems). For four isolates, sequencing of gdhB required
use of diluted amplification primers, as sequencing was unsuccessful with the
internal sequencing primers.
Editing and interpretation of electropherograms were performed visually and
with the assistance of the following software: Finch TV (http://www.geospiza.com
/Products/finchtv.shtml), Readseq (http://www.ebi.ac.uk/cgi-bin/readseq.cgi), and
Clustal X (16). Analysis of allele sequences and sequence type (ST) assignment
made use of the Oxford Acinetobacter baumannii MLST website (http://pubmlst
.org/abaumannii/) (14). The eBURST diagram was constructed by V3 software
(http://eburst.mlst.net/), using all available data from previous publications (3, 9,
12, 18, 21, 29) and unpublished data from the online database, where the
submitter of the data consented to its use.
Typing using rep-PCR. Repetitive sequence-based PCR (rep-PCR) was per-
formed with the semiautomated Diversilab system (bioMerieux, Melbourne,
Australia), according to the manufacturer’s instructions. Diversilab fingerprints
were analyzed with the Diversilab software using the Pearson correlation statis-
tical method to determine clonal relationships.
PFGE. PFGE was performed after digestion of genomic DNA with ApaI (New
England Biolabs, Beverley, MA), as described previously (25), and the results
were analyzed using Bionumerics software (Applied Maths, Belgium).
RESULTS
Of 33 isolates selected for analysis, 31 were blaOXA-51-like
positive. These isolates that were confirmed to be A. baumannii
underwent molecular typing and were examined for the pres-
ence of blaOXA-23.
MLST, antibiotic susceptibility, and blaOXA-23. MLST find-
ings and the associated antibiograms and blaOXA-23 results are
summarized in Tables 1 and 2. It must be noted that many ST
designations on the A. baumannii MLST website have changed
since the publication of relevant studies (9, 10, 18, 20, 21), to
avoid conflict with an earlier publication (3). For example,
ST92 was previously referred to as ST22. Changes relevant to
the current study are listed in Table 3.
ST92 was the dominant sequence type (22 of 31 isolates) and
was found in the hospital over the period from 2000 to 2008.
ST92 is also the most frequently isolated and founding geno-
type of the largest and most widespread clonal complex (CC),
TABLE 1. STs and allele numbers of Acinetobacter baumannii isolates, by year isolated
Isolate no. Yr isolated ST
Allele no.
gltA gyrB gdhB recA cpn60 gpi rpoD
Q48, Q47, Q57 2000 92 1 3 3 2 2 7 3
Q5, Q50, Q6, Q7 2001 92 1 3 3 2 2 7 3
Q51, Q52, Q53 2002 92 1 3 3 2 2 7 3
Q10, Q11 2004 92 1 3 3 2 2 7 3
Q12 2005 92 1 3 3 2 2 7 3
Q13, Q15, Q16, Q17, Q19, Q21 2006 92 1 3 3 2 2 7 3
Q25, Q26, Q28 2008 92 1 3 3 2 2 7 3
Q45 1998 69 1 46 3 2 2 58 3
Q1 1999 69 1 46 3 2 2 58 3
Q54 2002 69 1 46 3 2 2 58 3
Q18, Q20 2006 73 1 47 53 1 1 59 32
Q46, Q47 1999 125a 1 52a 59a 12 1 18 44a
Q55 2003 126a 10 53a 4 11 4 64 5
Q22 2007 127a 1 33 57a 11 26 11 6
a Novel.
TABLE 2. Antibiogram and blaOXA-23 result, by sequence type
ST No. of isolates
Antibiotic resistancea
blaOXA-23
Gentamicin Tobramycin Amikacin Ciprofloxacin Meropenem
92 22 R (21/22) R (12/22) S (19/22) R R Present
69 3 R (2/3) R (2/3) R R S Absent
73 2 R R S S R Present
125 2 R R R R R Present
126 1 R S R R S Absent
127 1 S S S S R Present
a R, nonsusceptible (including resistant and intermediate); S, susceptible. Numbers in parentheses indicate the number of strains with the indicated susceptibility/total
number of strains.










CC92, of A. baumannii (Fig. 1). Within CC92, ST92 (18), ST6
(3), ST98 (10), and ST118 (18) have previously been shown to
be representatives of European clone 2 (EU2) or worldwide
clonal lineage 2 (WW2) by other typing methods. All of the
isolates with this sequence type were carbapenem and cipro-
floxacin resistant but had variable susceptibilities to aminogly-
cosides. All of the isolates were also blaOXA-23 positive.
Three isolates were ST69. This is a double-locus variant
(DLV) of multiple STs within CC92, implying a close relation-
ship; however, an intervening single-locus variant (SLV) has
not yet been identified, so it cannot be considered a member of
CC92 by conservative definition (8). ST69 isolates were cipro-
floxacin and amikacin resistant but carbapenem susceptible
and blaOXA-23 negative. This phenotype was identified in only
a small number of isolates, namely, isolates Q1 (isolated in
1998), Q45 (isolated in 1999), and Q54. Q54 was isolated on
the day of admission from a patient transferred from Indonesia
in 2002. In spite of the apparent repeated introduction of this
ST, there was no evidence of persistence.
ST73 isolates were unique among local carbapenem-resis-
tant strains; they possessed a distinct pulsotype and were cip-
rofloxacin susceptible. Only four isolates with this phenotype
and pulsotype were detected, and all of these were isolated
from patients over a 4-month period in 2006. The index ST73
isolate was cultured from a patient who had been transferred
from Papua New Guinea. ST73 is a singleton by MLST and has
previously been described in South Korea (20).
Three novel singleton STs were identified. ST125 was
present in the hospital in 1999 only and was resistant to all
aminoglycosides, ciprofloxacin, and meropenem. The source of
TABLE 3. New designations for previously published sequence types discussed in the texta
Current designation Previous designation
ST Allelic profile ST Allelic profile Reference(s)
92 1-3-3-2-2-7-3 22 1-3-3-2-2-7-3 Park et al. (20), Mugnier et al. (18), Fu et al. (9), Ho et al. (12),
Hamouda et al. (10)
69 1-46-3-2-2-58-3 28 1-21-3-2-2-2-3 Park et al. (20)
73 1-47-53-1-1-59-32 32 1-22-19-1-1-23-18 Park et al. (20
a During December 2009/January 2010, changes were made to the MLST website (http://pubmlst.org/abaumannii/) to correct doubly allocated numbers to avoid
conflict with an earlier publication (3). A complete list of changes is available at the website.
FIG. 1. eBURST population snapshot of A. baumannii constructed from previous publications where official sequence types have been
assigned, plus unpublished data from the A. baumannii MLST website, where permission for use was granted by the submitter of the data. CC92
is currently the largest clonal complex. STs 19, 69, 9, 123, 28, 29, and 30 have double-locus-variant relationships with members of CC92 and are
therefore closely related, although they are not considered members of the CC by conservative definition.










the index case is unknown. The ST126 isolate (isolate Q55) had
an antibiotic susceptibility profile similar to that of the ST69
isolates (i.e., it was resistant to amikacin and ciprofloxacin but
susceptible to meropenem); however, these two STs were un-
related. The ST127 isolate (isolate Q22) was cultured from a
patient 1 week after admission to the ICU; Q22 was resistant
to meropenem only and possessed a blaOXA-23 resistance de-
terminant.
Rep-PCR and PFGE. A dendrogram constructed from rep-
PCR results is presented in Fig. 2. The results of the three
typing methods were generally concordant. By rep-PCR, ST69
clustered 95% with ST92. By PFGE also, ST69 clustered
among ST92 isolates (data not shown). This suggests that ST69
may belong to CC92, even though an SLV to link it to the
complex by MLST has not yet been identified. Some isolates
were indistinguishable by both rep-PCR and PFGE, despite
being cultured from patients many years apart (e.g., 7 years for
isolates Q6 and Q28 and 6 years for isolates Q28 and Q53,
respectively).
DISCUSSION
In this study we have examined the epidemiology of multi-
drug-resistant A. baumannii at a single institution longitudi-
nally over 10 years. We found that in spite of six different STs
being represented by non-wild-type A. baumannii isolates
tested, ST92 dominated heavily and was isolated from 2000 to
2008. Within ST92 there were diverse, but related, pulsotypes
and rep-PCR patterns. The only previous comparison of a
large group of A. baumannii isolates by PFGE and MLST
showed an unexpected divergence of sequence types by PFGE
for a geographically diverse collection of isolates (10). In this
study, the sequence types cluster together. These differences
likely reflect the sources of the strains comprising the two
collections. The only discrepant result between the typing
methods was that ST69 isolates clustered among ST92 isolates
by PFGE and rep-PCR. However, these ST69 isolates had a
distinct epidemiology and phenotype consistent with the dif-
ferentiation by MLST.
Our analysis identified isolates with indistinguishable pulso-
types or rep-PCR patterns separated by 6 and 7 years, respec-
tively. This suggests clonal spread of a successful A. baumannii
strain. In contrast, although there was introduction and trans-
mission of ST69 (on two occasions), ST73, and ST125, we did
not find evidence of the persistence of any of these STs for
more than 1 year. Possible explanations for the repeated iso-
lation of ST92 for nearly 10 years include readmission of pre-
viously colonized local patients (the potential duration of car-
riage is currently uncertain), reintroduction from interhospital
transfers, and long-term persistence in the hospital environ-
ment, in spite of intensive infection control efforts. Our results
and the known ability of this organism to resist desiccation (23)
support the latter possibility. Previous studies using an alter-
native MLST scheme have also shown repeated isolation of
ST2 isolates, which are also representatives of EU2, including
isolates that directly correspond to ST92 (18), in a single lo-
cation (5) or geographic region (7) over long periods of time,
but without the continuity at one site presented here.
On a global scale, ST92 is the predicted founder of CC92,
the largest and most geographically diverse clonal complex by
MLST. The results presented here confirm that our facility in
Australia is included in this global epidemic. CC92 corre-
sponds to EU2/WW2 on the basis of previous typing results by
other methods for members of the clonal complex, including
ST92 and ST118 (18). Further, an EU2 reference strain, RUH
134, has been reported in previous publications both to be ST6
(3) and to have an allelic profile corresponding to that of ST98
(10) by this MLST scheme. It is unclear why the reference
strain has given two STs, but ST6 and ST98 are SLVs that differ
by only one nucleotide in the gyrB locus. Our rep-PCR results
also show similarities between ST92 and WW2 (11), though
this is an inferior method for comparison between laboratories.
Although ST92 is heavily represented in the current MLST
data set, we cannot rule out the possibility that it may not be
truly representative of the diversity and relative abundance of
A. baumannii STs. There is presumably a bias toward investi-
gation and typing of strains resistant to multiple antimicrobials.
Indeed, this is the case for our collection of isolates, as the
antibiotic-resistant strains were those that had been stored for
potential future study, and half the strains that we tested were
FIG. 2. Dendrogram of A. baumannii rep-PCR patterns by the
Pearson correlation method. Isolate number, year of isolation, and ST
are also shown.










isolated during outbreaks. We attempted to overcome this by
including a number of diverse sporadic strains in our analyses;
over half of these were, in fact, ST92. We note also that we
tested only a representative subset of the total number of A.
baumannii isolates collected from 1998 to 2008, and thus, it is
possible that some important clones were missed. Globally,
there is also likely to be temporal and geographic bias related
to the availability of sequencing technology. For example,
eBURST analysis of European strains in the database identi-
fies ST98 as the founder of the dominant carbapenem-resistant
clonal complex, whereas ST92 is identified as the founder if
Asia/Oceania strains are analyzed. The diversity within clonal
complexes and the designation of putative founders may
change with the collection of more sequence typing data.
In the A. baumannii isolates examined here, similar antibi-
otic resistance profiles were seen within STs. The presence of
blaOXA-23 correlated closely with carbapenem resistance, as
has previously been the case where Australian strains have
been tested (17, 27), including a single ST92 isolate (16). How-
ever, antibiotic resistance profiles are known to be an inaccu-
rate predictor of clonality for A. baumannii (1, 6, 11, 13, 19),
and there is also diversity of antibiotic resistance determinants
within strains that are related by MLST. For example, carbap-
enem-susceptible ST92 isolates are widespread in China (9),
and carbapenem-resistant ST69 isolates have been identified in
South Korea (21), in contrast to the antibiotic susceptibility
patterns of our isolates. The large number of carbapenem-
susceptible ST92 isolates in China supports the notion that
antibiotic resistance may not be the primary determinant of
hospital adaptiveness for this clone.
For A. baumannii of CC92/WW2/EU2, the ability to persist
for over 9 years in a single hospital and the variable antibiotic
susceptibility of CC92 (and within ST92) suggest that adapta-
tion to the hospital environment, as well as antibiotic resis-
tance, may be important for the success of A. baumannii as a
nosocomial pathogen. This raises the question of why this
clonal complex has been so successful. With the progressive
accumulation of global data, MLST is proving to be a powerful
tool for the study of A. baumannii epidemiology, and the ad-
dition of Australian data adds new evidence for the intercon-
tinental spread of the most successful clonal complex. Colistin-
resistant isolates of ST92 have recently been described in
South Korea (21), a further step toward a truly panresistant
epidemic A. baumannii clone. In order to fully understand and
combat multidrug-resistant nosocomial A. baumannii, the
mechanisms of hospital adaptiveness beyond antibiotic resis-
tance demand more attention.
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